NUK - logo
E-viri
Recenzirano Odprti dostop
  • Pelvic Discontinuity Treate...
    Taunton, Michael J.; Fehring, Thomas K.; Edwards, Paul; Bernasek, Thomas; Holt, Ginger E.; Christie, Michael J.

    Clinical orthopaedics and related research, 02/2012, Letnik: 470, Številka: 2
    Journal Article, Conference Proceeding

    Background Pelvic discontinuity is an increasingly common complication of THA. Treatments of this complex situation are varied, including cup-cage constructs, acetabular allografts with plating, pelvic distraction technique, and custom triflange acetabular components. It is unclear whether any of these offer substantial advantages. Questions/purposes We therefore determined (1) revision and overall survival rates, (2) discontinuity healing rate, and (3) Harris hip score (HHS) after treatment of pelvic discontinuity with a custom triflange acetabular component and (4) the cost of this reconstructive operation compared to other constructs. Methods We retrospectively reviewed 57 patients with pelvic discontinuity treated with revision THA using a custom triflange acetabular component. We reviewed operative reports, radiographs, and clinical data for clinical and radiographic results. We also performed a cost comparison with utilization of other techniques. Minimum followup was 24 months (average, 65 months; range, 24–215 months). Results Fifty-six of 57 (98%) were free of revision for aseptic loosening at latest followup. Fifty-four (95%) were free of revision of the triflange component for any reason. Thirty-seven (65%) were free of revision for any reason. Twenty-eight (49%) were free of revision for any reason and free of any component migration and had a healed discontinuity. Forty-six (81%) had a stable triflange component with a healed pelvic discontinuity. Average HHS was 74.8. The costs of the custom triflange implants and a Trabecular Metal ® cup-cage construct were equivalent: $12,500 and $11,250, respectively. Conclusions In this group of patients with osteolytic pelvic discontinuity, triflange implants provided predictable mid-term fixation at a cost equivalent to other treatment methods. Level of Evidence Level IV, therapeutic study. See the Guidelines for Authors for a complete description of levels of evidence.